Holen Sie sich die Stockscreener-App
16.75
0.39%
0.065
Schlusskurs vom Vortag:
$16.69
Offen:
$16.96
24-Stunden-Volumen:
5.19M
Relative Volume:
0.94
Marktkapitalisierung:
$13.37B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-1.21B
KGV:
-10.45
EPS:
-1.6039
Netto-Cashflow:
$-387.48M
1W Leistung:
+7.34%
1M Leistung:
+14.76%
6M Leistung:
-13.54%
1J Leistung:
-19.72%
1-Tages-Spanne:
$16.66
$17.32
1-Wochen-Bereich:
$15.18
$19.09
52-Wochen-Spanne:
$12.07
$29.23
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.75 | 12.45B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20 - Moomoo
Summit Therapeutics Stock Climbs Wednesday: What's Happening? - Benzinga
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 247wallst.com
Leerink Partners Sticks to Its Hold Rating for Summit Therapeutics (SMMT) - theglobeandmail.com
Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT) - theglobeandmail.com
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - reuters.com
AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug - MedCity News
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says - marketscreener.com
SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet - StocksToTrade
Summit Therapeutics Rises as AstraZeneca Backs Ivonescimab With $2 Billion Investment - Quiver Quantitative
Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab - Seeking Alpha
How Summit Therapeutics Stock Could Surge 162% After AstraZeneca Investment - Barron's
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics - Pharmaceutical Executive
Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal - timothysykes.com
AstraZeneca Invests in Summit Therapeutics after Year of Speculation - Benzinga
AstraZeneca Invests $2B in Summit for Cancer Drug Dev - Rediff MoneyWiz
Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal And Trial Wins - StocksToTrade
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Australia
Summit Therapeutics Soars On $2B AstraZeneca Bet And Trial Wins - StocksToTrade
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Form 8K Summit Therapeutics PLC ADR For: 29 September By Investing.com - Investing.com Nigeria
AstraZeneca to invest $2bn in Summit for ADC combination therapies - Yahoo Finance
Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal - Investing.com Canada
Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment - Yahoo Finance
Summit soars after $2 billion investment from AstraZeneca for cancer therapies - reuters.com
Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca - TradingView
AMD, Nvidia, Navitas, Summit Therapeutics, Fair Isaac, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
AstraZeneca invests $2bn in Summit Therapeutics - marketscreener.com
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer - Cambridge Network
AstraZeneca invests $2bn in Summit Therapeutics to develop cancer drug - Business Weekly
AstraZeneca invests $2B in Summit Therapeutics for ADC trials By Investing.com - Investing.com Australia
Summit Therapeutics Inc. stock jumps on AstraZeneca’s $2B deal, but chart stays weak - The Cryptonomist
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca invests $2 billion in Summit Therapeutics By Investing.com - Investing.com South Africa
Summit Therapeutics (SMMT) Secures $2B AstraZeneca Investment, S - GuruFocus
Update: Summit Therapeutics Shares Jump as AstraZeneca's Plan to Invest $2 Billion - Yahoo Finance
AstraZeneca to invest USD2 billion in Summit Therapeutics - marketscreener.com
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs - WSJ
Summit shares surge after-hours on $2 billion AstraZeneca equity deal - Yahoo Finance
Summit Therapeutics rises after AstraZeneca commits $2B investment - TradingView
Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal - Bloomberg.com
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics - Business Wire
Summit Therapeutics Inc. announced that it expects to receive $2 billion in funding from AstraZeneca PLC - marketscreener.com
Bernstein Reaffirms Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings - stocktwits.com
Why Is SMMT Stock Tumbling Today? - stocktwits.com
Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Summit Therapeutics plc (SMMT) stock price, news, quote and history - Yahoo Finance UK
Summit Therapeutics Inc. (SMMT) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):